Niraxostat (Y-700; 1 mg/kg) has high oral bioavailability (84.1%) and is almost not excreted through the kidneys. It is mainly eliminated through the liver[1].
Niraxostat (Y- 700; 1-10 mg/kg; oral; single dose) dose-dependently reduces plasma urate levels in oxonate-treated rats [1].
Niraxostat (Y-700 ; 0.3-3 mg/kg; Oral; Single dose) In normal rats, dose-dependently reduces urinary excretion of urate and allantoin while increasing excretion of hypoxanthine and xanthine [1].
Pharmacokinetic Analysis of Niraxostat (Y-700) in normal rats[1]
| Route | Dose (mg/kg) | tmax (h) | Cmax (μg/ml) | AUC0-∞ (μg/h/ml) | t1/2 (h) |
| PO | 0.3 | 0.5 | 0.43 | 2.07 | 5.0 |
| PO | 1 | 0.3 | 1.8 | 7.01 | 3.2 |
| PO | 3 | 0.5 | 6.49 | 30.31 | 2.7 |
| IV | 1 | / | 3.97 | 8.34 | 2.5 |
![1-[3-Cyano-4-(2,2-dimethyl-propoxy)-phenyl]-1H-pyrazole-4-carboxylic acid Structure](/CAS/GIF/206884-98-2.gif)
